CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell 11,500,000 shares of its common stock in an underwritten offering at a price to the public of $38.50 per share, which would result in aggregate gross proceeds of $442.8 million. Vertex has granted the underwriters an option to purchase up to an additional 1,500,000 shares of its common stock on the same terms and conditions.
